Effect of a new leuprorelin formulation on testosterone levels in patients with advanced prostate cancer

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.22, Iss.4, 2006-04, pp. : 649-655

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Testosterone Levels in Benign Prostatic Hypertrophy and Prostate Cancer

Urologia Internationalis, Vol. 80, Iss. 2, 2008-03 ,pp. : 134-140

Karger

Access to resources Recommend Favorite

Leuprorelin Three-Month Depot in the Treatment of Advanced and Metastatic Prostate Cancer: Long-Term Follow-Up Results

Urologia Internationalis, Vol. 60, Iss. 2, 1998-04 ,pp. : 18-24

Karger

Access to resources Recommend Favorite

An Evaluation of Pharmacokinetics and Pharmacodynamics of Leuprorelin Acetate 3M-Depot in Patients with Advanced and Metastatic Carcinoma of the Prostate

Urologia Internationalis, Vol. 60, Iss. 1, 1998-02 ,pp. : 33-40

Karger

Access to resources Recommend Favorite

Failure to Maintain a Suppressed Level of Serum Testosterone during Long-Acting Depot Luteinizing Hormone-Releasing Hormone Agonist Therapy in Patients with Advanced Prostate Cancer

Urologia Internationalis, Vol. 77, Iss. 2, 2006-08 ,pp. : 135-138

Karger

Access to resources Recommend Favorite

Preoperative Plasma Levels of Total Testosterone Associated with High Grade Pathology-Detected Prostate Cancer: Preliminary Results of a Prospective Study in a Contemporary Cohort of Patients

Current Urology, Vol. 10, Iss. 2, 2017-05 ,pp. : 72-80

Karger

Access to resources Recommend Favorite